The collaboration centers on the OhmX Platform, a technology that integrates precision electronics and nanofluidics to map genome structures. By utilizing CRISPR/Cas9 to optimize labeling sites, the researchers intend to resolve the D4Z4 repeat units characteristic of FSHD—a task that currently forces labs to rely on outdated, radioactive techniques like Southern blotting. Prof. Silvère van der Maarel of the Leiden University Medical Center noted that these traditional methods are significant bottlenecks in modern research. His team expects the OhmX system to provide the structural variant resolution necessary to handle complex rearrangements and proximal deletions that standard sequencing tools fail to detect.

Beyond muscular dystrophy, Nabsys presented new data at the 2026 European Society of Human Genetics meeting confirming the platform's utility in identifying repeat expansions linked to Fragile X syndrome and Friedreich's ataxia. By combining the OhmX hardware with Hitachi High-Tech’s bioinformatics pipelines, the company demonstrated the ability to call FMR1 and FXN repeats with high accuracy. According to Nabsys CEO Barrett Bready, this integration of CRISPR technology expands the reach of electronic genome mapping, positioning it as a robust, high-resolution alternative for researchers investigating challenging genomic regions.